Literature DB >> 14676024

The quality of life of HIV-infected women is associated with psychiatric morbidity.

M A Tostes1, M Chalub, N J Botega.   

Abstract

This study evaluated the effect of clinical, demographic and psychiatric factors on the health-related quality of life of 76 women with HIV infection seen in two HIV reference centres in Brazil. The generic questionnaire for evaluation of Health-Related Quality of Life (SF-36), the Hospital Anxiety and Depression Scale (HAD) and the Clinical Interview Schedule (CIS-R) were used. The statistical tests included the covariance analysis. The patients' mean age was 37.4 years; 44.7% had less than 8 years of schooling. A total of 44.8% were asymptomatic, 28.9% symptomatic non-AIDS and 26.3% had AIDS. Most (77.6%) used two or three kinds of antiretrovirals; 36.8 and 30.3% achieved scores for anxiety and depression, respectively (HAD); and 48.7% for conspicuous psychiatric morbidity (CIS-R). The sub-group of the non-AIDS symptoms (clinical stage B) showed the worst quality of life. The variables which better explained the scoring variation on both the mental and physical components of the SF-36 were related to mental health. The more mental symptoms present, the worse the health-related quality of life. We must rethink care strategies in the area of mental health which are directed toward HIV+ patients, by virtue of the levels of mental symptoms found and the request for care which the research revealed.

Entities:  

Mesh:

Year:  2004        PMID: 14676024     DOI: 10.1080/09540120410001641020

Source DB:  PubMed          Journal:  AIDS Care        ISSN: 0954-0121


  18 in total

1.  Challenges in addressing depression in HIV research: assessment, cultural context, and methods.

Authors:  Jane M Simoni; Steven A Safren; Lisa E Manhart; Karen Lyda; Cynthia I Grossman; Deepa Rao; Matthew J Mimiaga; Frank Y Wong; Sheryl L Catz; Michael B Blank; Ralph DiClemente; Ira B Wilson
Journal:  AIDS Behav       Date:  2011-02

2.  The indirect impact of antiretroviral therapy: Mortality risk, mental health, and HIV-negative labor supply.

Authors:  Victoria Baranov; Daniel Bennett; Hans-Peter Kohler
Journal:  J Health Econ       Date:  2015-08-24       Impact factor: 3.883

Review 3.  [Aspects of rehabilitation in HIV and AIDS].

Authors:  G H Franke; K P Hackbarth; A Potthoff; N Brockmeyer
Journal:  Hautarzt       Date:  2005-07       Impact factor: 0.751

Review 4.  What is the relevance of mental health to HIV/AIDS care and treatment programs in developing countries? A systematic review.

Authors:  Pamela Y Collins; Alea R Holman; Melvyn C Freeman; Vikram Patel
Journal:  AIDS       Date:  2006-08-01       Impact factor: 4.177

5.  Lifetime suicide attempt history, quality of life, and objective functioning among HIV/AIDS patients with alcohol and illicit substance use disorders.

Authors:  Kimberly N Walter; Nancy M Petry
Journal:  Int J STD AIDS       Date:  2015-05-06       Impact factor: 1.359

6.  Multivitamin supplementation in HIV-positive pregnant women: impact on depression and quality of life in a resource-poor setting.

Authors:  M C Smith Fawzi; S F Kaaya; J Mbwambo; G I Msamanga; G Antelman; R Wei; D J Hunter; W W Fawzi
Journal:  HIV Med       Date:  2007-05       Impact factor: 3.180

7.  Anxiety and depression symptoms as risk factors for non-adherence to antiretroviral therapy in Brazil.

Authors:  Lorenza Nogueira Campos; Mark Drew Crosland Guimarães; Robert H Remien
Journal:  AIDS Behav       Date:  2008-07-22

8.  AIDS treatment and mental health: evidence from Uganda.

Authors:  Edward N Okeke; Glenn J Wagner
Journal:  Soc Sci Med       Date:  2013-05-31       Impact factor: 4.634

9.  Quality of life of people living with HIV and AIDS and antiretroviral therapy.

Authors:  Oluwafemi O Oguntibeju
Journal:  HIV AIDS (Auckl)       Date:  2012-08-06

10.  Quality of life among HIV-infected patients in Brazil after initiation of treatment.

Authors:  Lorenza Nogueira Campos; Cibele Comini César; Mark Drew Crosland Guimarães
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.